Recent 8-K filings for VIR

• May 28, 2026, 9:01 AM ET leadership materiality 0.65 neutral item 5.02item 5.07

  Vir Biotechnology director Saira Ramasastry resigns; board shrinks to 7; annual meeting elects directors

  Saira Ramasastry steps down from board and audit committee effective May 26, 2026, due to business conflict; no disagreement with company.

• May 6, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Vir Bio Q1 net loss $125.7M; cash $809.3M; positive CHD data; VIR-5500 collaboration closed

  Net loss of $125.7M ($0.85 per share) vs $121M ($0.88) in Q1 2025.

• April 10, 2026, 7:59 PM ET leadership materiality 0.60 negative item 5.02

  Vir Biotechnology CMO Mark Eisner to step down effective April 24, 2026

  Mark Eisner, EVP and Chief Medical Officer, leaving role on April 24, 2026.

• March 2, 2026, 6:59 PM ET other material materiality 0.70 negative item 8.01

  Vir Biotechnology closes $172.5M equity offering; underwriters exercise full over-allotment

  Sold 20,294,117 shares of common stock at $8.50 per share, raising ~$172.5M in gross proceeds.

• February 26, 2026, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01

  Vir Biotechnology prices $150M public offering of 17.6M shares at $8.50/share

  Offering of 17,647,059 shares of common stock at $8.50 per share; over-allotment option for 2,647,058 shares.

• February 23, 2026, 6:59 PM ET other material materiality 0.95 positive item 1.01item 2.02item 3.02item 8.01item 9.01

  Vir Biotechnology enters global strategic collaboration with Astellas for VIR-5500 prostate cancer T-cell engager

  Vir Bio will receive $335 million in upfront and near-term payments, including $240M cash and $75M equity at 50% premium.

• January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 2.02item 7.01item 9.01

  Vir Bio: 88% HDV RNA undetectable at Week 96 in combo arm; cash ~$781M, runway to Q4 2027

  Phase 2 SOLSTICE: 88% (21/24) of combo arm achieved undetectable HDV RNA at Week 96 vs 46% (11/24) monotherapy.

• December 16, 2025, 6:59 PM ET other material materiality 0.75 positive item 1.01item 8.01item 9.01

  Vir Bio licenses CHD combo to Norgine for EUR 55M upfront, up to EUR 495M milestones; cash runway extended to Q4 2027

  Exclusive commercial license for tobevibart+elebsiran in Europe, Australia, New Zealand for chronic hepatitis delta.

• November 5, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Vir Biotech Q3 net loss $163M ($1.17/sh); ECLIPSE enrollment ahead of schedule

  Net loss $163.1M ($1.17/sh) vs $213.7M ($1.56) in Q3 2024; revenues $0.2M.

• August 6, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Vir Biotechnology Q2 net loss $111.0M; cash $892.1M; ECLIPSE program underway

  Net loss $111.0M ($0.80/share) vs $138.4M ($1.02) in Q2 2024; revenue $1.2M down from $3.1M.

• July 24, 2025, 7:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Vir doses first patient in Phase 1 trial of EGFR-TCE VIR-5525; triggers $75M milestone payment to Sanofi

  First patient dosed in Phase 1 trial of VIR-5525, a dual-masked T-cell engager targeting EGFR, in solid tumors (NSCLC, CRC, HNSCC, cSCC).

• May 9, 2025, 7:59 PM ET other material materiality 0.70 negative item 8.01item 9.01

  Vir Biotech reports HBsAg loss in MARCH study but halts Phase 3 for chronic HBV without partner

  HBsAg loss 24 weeks post-treatment: 17% (3/18) and 21% (3/14) in low baseline HBsAg patients with tobevibart+elebsiran without/with PEG-IFNα.

• May 7, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Vir Biotech Q1 net loss $121M; launches Phase 3 hepatitis delta program; cash into mid-2027

  Net loss of $121.0M ($0.88 per share) vs $65.3M ($0.48) in Q1 2024; revenue $3.0M vs $56.4M.

• February 26, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Vir Biotechnology reports Q4 and full year 2024 financial results and pipeline updates

  Cash, cash equivalents and investments of $1.10 billion as of Dec 31, 2024, providing cash runway into mid-2027.

• January 8, 2025, 6:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Vir Biotech reports encouraging Phase 1 data: 50% tumor shrinkage (VIR-5818), 58% PSA50 (VIR-5500)

  VIR-5818 (HER2): 50% (10/20) tumor shrinkage at doses ≥400 µg/kg; cPR in 33% (2/6) HER2+ CRC.

• October 31, 2024, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Vir Biotech Q3 net loss $213.7M; closes Sanofi TCE licensing deal, appoints new CFO

  Net loss $213.7M ($1.56 per share) vs $163.4M ($1.22) in Q3 2023; revenue $2.4M, down from $2.6M.

• September 10, 2024, 7:59 PM ET M&A materiality 0.85 positive item 2.01item 5.02item 7.01item 9.01

  Vir closes $100M Sanofi license deal for three T-cell engagers; appoints new CFO

  Closed exclusive worldwide license with Sanofi for 3 clinical-stage masked TCEs (SAR446309, SAR446329, SAR446368) and PRO-XTEN platform for oncology/infectious disease.

• August 1, 2024, 7:59 PM ET M&A materiality 0.90 positive item 1.01

  Vir Biotechnology licenses three clinical-stage masked T-cell engagers from Sanofi for $100M upfront

  Upfront payment of $100M plus $75M escrowed milestone for SAR446368 (AMX-525) first-in-human dosing by 2026.

• August 1, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 2.05item 9.01

  Vir Bio Q2 net loss narrows to $138M; initiates restructuring cutting 25% of workforce

  Net loss of $138.4M ($1.02/sh) vs $194.8M ($1.45/sh) in Q2 2023; cash and investments $1.43B, down $78M in quarter.

• June 26, 2024, 7:59 PM ET regulatory materiality 0.70 positive item 8.01item 9.01

  Vir Biotech gets FDA IND clearance & Fast Track for hepatitis delta combo therapy

  FDA cleared IND and granted Fast Track for tobevibart + elebsiran for chronic hepatitis delta.

• June 5, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  Vir reports high virologic response in Phase 2 SOLSTICE hepatitis delta trial

  De novo tobevibart+elebsiran combination: 64% (7/11) combined endpoint at week 24.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.95 · Median 0.70 · Most common event other_material

8 positive 6 negative 11 neutral

source · VIR on sec.gov